Pennsylvania 2025_0 Regular Session Status: In Committee 28 D cosponsors

HB 305 — An Act amending the act of May 17, 1921 (P.L.682, No.284), known as The Insurance Company Law of 1921, in casualty insurance, providing for coverage for insulin.

Last action — Re-referred to INSURANCE, Oct. 29, 2025

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced January 23, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Prognosis

Stalled 26% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 29 sponsors

    1 primary, 28 co-sponsors signed on.

  • Single-party support

    Sponsorship is currently within one party (28 D).

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Summary

Establishing a $35 Cap on Insulin

Bill Text

How this bill changes current law

6 changes Share ↗

AI-generated reading aid from the bill's amendatory text — verify against the official bill.

This bill establishes a maximum copayment for insulin coverage under health insurance policies in Pennsylvania.

  • Section 635.11

    Coverage for Insulin.--(a) A health insurance policy providing prescription coverage of insulin may not impose on a covered individual a copayment, coinsurance or deductible of more than thirty-five dollars ($35) per thirty-day supply of insulin, regardless of the amount or type of insulin needed to fill the covered individual's prescription.

    It mandates a cap on costs for insulin for insured individuals.

  • Section 635.11

    (b) Nothing in this section shall prevent a health insurance policy from offering a lesser monthly price for a thirty-day supply of insulin than the price provided under subsection (a).

    It allows insurance policies to offer lower prices for insulin if they choose.

  • Section 635.11

    (c) The Insurance Department may promulgate regulations as necessary to implement and enforce the maximum price established under this section.

    It delegates authority to the Insurance Department to create regulations for enforcement.

  • Section 635.11

    (d) This section shall not apply to the following types of policies: (1) Accident only. (2) Fixed indemnity. (3) Limited benefit. (4) Credit. (5) Dental. (6) Vision. (7) Specified disease. (8) Medicare supplement. (9) CHAMPUS (Civilian Health and Medical Program for the Uniform Services) supplement. (10) Long-term care or disability income. (11) Workers' compensation. (12) Automobile medical payment.

    It specifies which insurance policies are excluded from the insulin coverage requirements.

  • Section 635.11

    (e) The Attorney General shall investigate pricing of prescription insulin drugs to ensure that adequate pricing is achieved and to determine if additional consumer protections are necessary. As part of this investigation, the Attorney General shall gather, compile and analyze information concerning business practices, pricing, data and other information regarding insulin prescription drug manufacturers' roles in the current prices of insulin prescription drugs.

    It requires the Attorney General to investigate insulin pricing and practices.

  • Section 635.11

    (f) The Attorney General shall submit the findings of the investigation under subsection (e) in a report to the General Assembly, which shall be made accessible to the public no later than one year after the effective date of this subsection. The report must include: (1) A summary of insulin pricing practices and factors that contribute to the pricing of health insurance plans. (2) Public policy recommendations to control and prevent overpricing of prescription insulin drugs made available to consumers in this Commonwealth. (3) Any other information the Attorney General finds necessary to complete the report.

    It mandates a public report by the Attorney General on insulin pricing and health insurance impacts within a year.

Action History

  1. Re-referred to INSURANCE, Oct. 29, 2025

  2. Reported with request to re-refer to INSURANCE, Oct. 29, 2025

  3. Referred to HEALTH, Jan. 23, 2025

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 28 co-sponsors · 224 not signed on

Sponsors (1)

Co-sponsors (28)

Not signed on (224)

224 members have not signed on to this bill.

Show all 224 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 305 do?
Establishing a $35 Cap on Insulin
Who sponsors HB 305?
HB 305 is sponsored by Jeanne McNeill (Democratic), Melissa Cerrato (Democratic), Steve Samuelson (Democratic), Ben Waxman (Democratic), Lisa A. Borowski (Democratic), MaryLouise Isaacson (Democratic), Benjamin V. Sanchez (Democratic), Tarah Probst (Democratic), Darisha K. Parker (Democratic), Arvind Venkat (Democratic), Kristine C. Howard (Democratic), Emily Kinkead (Democratic), Perry S. Warren (Democratic), Jose Giral (Democratic), Dan K. Williams (Democratic), La'Tasha D. Mayes (Democratic), BRENNAN, Chris Pielli (Democratic), Malcolm Kenyatta (Democratic), Tarik Khan (Democratic), Daniel J. Deasy (Democratic), Jennifer O'Mara (Democratic), Heather Boyd (Democratic), Andre D. Carroll (Democratic), G. Roni Green (Democratic), Joe Ciresi (Democratic), Keith S. Harris (Democratic), Rick Krajewski (Democratic), and Joseph C. Hohenstein (Democratic).
What is the current status of HB 305?
This bill is in committee in the House. Introduced January 23, 2025. It must pass committee before a floor vote.
Where can I track HB 305?
Track HB 305 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 305

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 305

Last checked for changes 7 days ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →